Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. (March 2023)

• Record Type: Journal Article
• Authors: Cookson, John; Pimm, Jonathan
• Is Part Of: BJPsych advances. Volume 29:Number 2(2023)
• Page Start: 145
• Page End: 150
• Publication Date: 2023-03
• Subjects: Partial dopamine agonists -- aripiprazole -- brexpiprazole -- cariprazine -- antipsychotics; Psychiatry -- Periodicals; 616.89005
• DOI: 10.1192/bja.2021.49
• Languages: English
• ISSNs: 2056-4678

Abstract

SUMMARY: Aripiprazole, brexpiprazole and cariprazine are partial dopamine (and serotonin) agonists developed as novel antipsychotics. This article discusses their pharmacology, evidence on their licensed and off-licence uses (including psychosis, mania, bipolar depression, Tourette syndrome and autism spectrum disorder) and side-effects. In schizophrenia, they have a low risk of Parkinsonism or hyperprolactinaemia, cause modest increases in body weight and are of moderate efficacy.